Nutricia

Global Oral Clinical Nutrition Market Predicted to Expand Significantly by 2028, Driven by Rising Chronic Diseases - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 5, 2023

The global oral clinical nutrition market is poised for substantial growth during the forecast period due to the increasing prevalence of chronic diseases and a growing emphasis on patient-centric care.

Key Points: 
  • The global oral clinical nutrition market is poised for substantial growth during the forecast period due to the increasing prevalence of chronic diseases and a growing emphasis on patient-centric care.
  • Additionally, the rise in malnutrition and related conditions like sarcopenia and cachexia is boosting the demand for oral clinical nutrition products.
  • Rising Chronic Diseases: The escalating incidence of chronic conditions such as diabetes, cardiovascular disease, and cancer is a significant driver of the global oral clinical nutrition market.
  • The comprehensive Global Oral Clinical Nutrition Market report covers market segmentation by indication, distribution channel, and region, highlighting industry trends and growth drivers.

Oral Clinical Nutrition Global Market Report 2023: Sector to Reach Grow by Over 5% Annually Through 2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 27, 2023

The "Oral Clinical Nutrition Market by Stage, Indication Sales Channel Outlook and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oral Clinical Nutrition Market by Stage, Indication Sales Channel Outlook and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The oral clinical nutrition market size is estimated to be USD 15,358.7 million in 2022 and is expected to witness a CAGR of 5.42% during the forecast period 2023-2033.
  • However, uncertain perceptions of therapeutic nutrition and a decline in birth rates are anticipated to hinder the market growth.
  • clinical nutrition plays a significant role in avoiding harmful effects for patients during procedures and allowing surgeons to operate in a controlled environment.

Europe Enteral Medical Nutrition Market Forecast Report 2022-2028 - Opportunities in the Use of Next Generation Technology for Proper Enteral Nutrition Feeding - ResearchAndMarkets.com

Retrieved on: 
Monday, January 23, 2023

The enteral medical nutrition market in Europe is expected to grow from US$ 4,042.08 million in 2022 to US$ 2,857.47 million by 2028.

Key Points: 
  • The enteral medical nutrition market in Europe is expected to grow from US$ 4,042.08 million in 2022 to US$ 2,857.47 million by 2028.
  • Therefore, the growing prevalence of gastrointestinal diseases, especially in developing countries, drives the growth of the enteral medical nutrition market.
  • Based on nutrition type, the Europe enteral medical nutrition market is segmented into supplemental and sole source.
  • Based on distribution channel, the Europe Enteral Medical Nutrition market is segmented into Hospital Pharmacies, Retail Stores and Other Pharmacies.

Enteral Feeding Formula Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Wednesday, December 21, 2022

The enteral feeding formula market is expected to reach $7.14 billion in 2026 at a compound annual growth rate (CAGR) of 7.32%.

Key Points: 
  • The enteral feeding formula market is expected to reach $7.14 billion in 2026 at a compound annual growth rate (CAGR) of 7.32%.
  • The regions covered in the enteral feeding formula market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The launch of new products provides customers with more options and increases demand for enteral feeding formulas, which drives the enteral feeding formula market.
  • The enteral feeding formulas market research report is one of a series of new reports that provides enteral feeding formulas market statistics, including enteral feeding formulas industry global market size, regional shares, competitors with a enteral feeding formulas market share, detailed enteral feeding formulas market segments, market trends and opportunities, and any further data you may need to thrive in the enteral feeding formulas industry.

Danone Supports American Families by Bringing Additional Baby Formula and New Online Resource

Retrieved on: 
Thursday, August 4, 2022

WHITE PLAINS, N.Y. and BROOMFIELD, Colo., Aug. 4, 2022 /PRNewswire/ -- Danone North America, the purpose-driven food and beverage leader, today announced alongside its Specialized Nutrition business, Nutricia, it will introduce a new specialty medical baby formula, to the U.S. market this Fall. Continuing its efforts to help families navigate the baby formula shortage, Danone has also launched an online website, https://operationformulaforfamilies.com, that will serve to connect parents with helpful resources.

Key Points: 
  • Continuing its efforts to help families navigate the baby formula shortage, Danone has also launched an online website, https://operationformulaforfamilies.com, that will serve to connect parents with helpful resources.
  • Pepticate is an extensively hydrolyzed, whey-based medical formula for children with cow's milk allergies.
  • Shane Grant, CEO at Danone North America, said:"Danone teams around the world have come together, harnessing our global capabilities to support babies and families at a critical time.
  • To further help parents and families navigate the formula shortage, Danone North America developed a new online resource, https://operationformulaforfamilies.com .

Freya Pharma Solutions Announces Appointment of Dr. Jan van der Mooren as Chief Medical Officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD

Retrieved on: 
Tuesday, April 12, 2022

AMSTERDAM, April 12, 2022 /PRNewswire/ -- Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD), today announced the appointment of Jan van der Mooren MD, PhD, MSc (picture below) as Chief Medical Officer as per April 2022. Dr. Van der Mooren is a medical doctor with additional education in Gynaecological Endocrinology and Epidemiology. He has been involved in clinical research since 1990. Prior to his appointment he was Senior Director of the Danone Nutricia Research Center in Utrecht, the Netherlands. Jan will be in the lead of Freya's steering committee overseeing the upcoming phase 3 study of Lybrido to confirm its efficacy in women suffering from FSIAD.

Key Points: 
  • Dr. Van der Mooren is a medical doctor with additional education in Gynaecological Endocrinology and Epidemiology.
  • Jan will be in the lead of Freya's steering committee overseeing the upcoming phase 3 study of Lybrido to confirm its efficacy in women suffering from FSIAD.
  • Dr. Van der Mooren brings to Freya three decades of life sciences experience in clinical development and medical affairs in nutrition, epidemiology, obstetrics and gynaecology.
  • Freya Pharma Solutions plans to conduct the pivotal phase 3 clinical trial to confirm the efficacy of Lybrido in women suffering from FSIAD.

Freya Pharma Solutions Announces Appointment of Dr. Jan van der Mooren as Chief Medical Officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD

Retrieved on: 
Tuesday, April 12, 2022

AMSTERDAM, April 12, 2022 /PRNewswire/ -- Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD), today announced the appointment of Jan van der Mooren MD, PhD, MSc (picture below) as Chief Medical Officer as per April 2022. Dr. Van der Mooren is a medical doctor with additional education in Gynaecological Endocrinology and Epidemiology. He has been involved in clinical research since 1990. Prior to his appointment he was Senior Director of the Danone Nutricia Research Center in Utrecht, the Netherlands. Jan will be in the lead of Freya's steering committee overseeing the upcoming phase 3 study of Lybrido to confirm its efficacy in women suffering from FSIAD.

Key Points: 
  • Dr. Van der Mooren is a medical doctor with additional education in Gynaecological Endocrinology and Epidemiology.
  • Jan will be in the lead of Freya's steering committee overseeing the upcoming phase 3 study of Lybrido to confirm its efficacy in women suffering from FSIAD.
  • Dr. Van der Mooren brings to Freya three decades of life sciences experience in clinical development and medical affairs in nutrition, epidemiology, obstetrics and gynaecology.
  • Freya Pharma Solutions plans to conduct the pivotal phase 3 clinical trial to confirm the efficacy of Lybrido in women suffering from FSIAD.

Immunicom Recruits Dr. Erdal Bozdoğan to Join Leadership Team

Retrieved on: 
Tuesday, December 14, 2021

Immunicom, Inc. , a clinical-stage biotech pioneering non-pharmaceutical immunotherapies, announced that Dr. Erdal Bozdoan has joined Immunicom as the companys General Manager in Turkey.

Key Points: 
  • Immunicom, Inc. , a clinical-stage biotech pioneering non-pharmaceutical immunotherapies, announced that Dr. Erdal Bozdoan has joined Immunicom as the companys General Manager in Turkey.
  • Dr. Bozdoan is known both for his track record of successful development and implementation of commercial strategies for international and regional product launches, and for his exceptional operational leadership skills.
  • Dr. Bozdoan previously served as General Manager at Takeda Pharmaceuticals Turkey, where he achieved excellent results while managing the marketing and commercialization strategy for Takedas oncology and specialty-care franchise in Turkey.
  • Experiencing the Immunicom teams tremendous enthusiasm and excitement for its groundbreaking work in the field of subtractive cancer therapy makes joining this team an incredible opportunity.

Clinical Nutrition Market - Global Outlook and Forecast 2021-2026 with Abbott Laboratories, Baxter International, B. Braun, Danone, and Nestle Health Science Dominating - ResearchAndMarkets.com

Retrieved on: 
Monday, July 19, 2021

The global clinical nutrition market research report includes a detailed segmentation by route of administration, age group, product type, application, distributional channels, end-users, geography.

Key Points: 
  • The global clinical nutrition market research report includes a detailed segmentation by route of administration, age group, product type, application, distributional channels, end-users, geography.
  • Focusing on health and wellness, aging well, and disease prevention by consumers, healthcare providers are demanding preventive clinical nutrition products and are experiencing rapid growth.
  • Global brands such as Abbott, Nestle, Nutricia, and Fresenius Kabi offer parenteral, enteral, and oral nutrition products for infants.
  • Abbott Laboratories, Baxter International, B. Braun, Danone, and Nestle Health Science are the major players.

Integral Ad Science Announces New Appointments To Board of Directors

Retrieved on: 
Thursday, July 8, 2021

"I'm proud that our board of directors represents our profound commitment to diversity and inclusion at IAS as we build for the future," said Lisa Utzschneider, CEO of IAS.

Key Points: 
  • "I'm proud that our board of directors represents our profound commitment to diversity and inclusion at IAS as we build for the future," said Lisa Utzschneider, CEO of IAS.
  • Previously, Heller served as the Executive Vice President and President of Nutricia, the Specialized Nutrition Division of Danone.
  • The IAS Board of Directors includes diverse representation from industry experts who partner with the company's leadership on continued business innovation.
  • Integral Ad Science (IAS) is a global leader in digital media quality.